Pharmaceuticals News and Research

RSS

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010

Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology annual meeting in Chicago.

21 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Abbott to acquire Piramal's Healthcare Solutions business

Abbott announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market.

21 May 2010

COTI reports positive results from first phase of HIV integrase inhibitor discovery program

Critical Outcome Technologies Inc. today announced positive results from the first phase of its HIV integrase inhibitor discovery program. These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.

21 May 2010

EpiCept launches Ceplene in Germany

EpiCept Corporation today announced the commercial launch of Ceplene (R) (histamine dihydrochloride) in Germany. The launch is being conducted by Meda AB, as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010.

21 May 2010

WHA addresses counterfeit medicines

Discussions about combatting counterfeit medicines continued at the 63rd World Health Assembly (WHA) in Geneva on Wednesday, Agence France-Press reports

21 May 2010

GSK, EMBL-EBI, NLM and CDD collaborate to apply principles of open source to drug discovery for malaria

GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine (NLM) and the U.S.-based informatics service provider Collaborative Drug Discovery (CDD) to make freely available key scientific information on more than 13,500 compounds that could ultimately lead to new treatments for malaria.

20 May 2010

Invida Group completes joint venture agreement with MUGI

Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI.

20 May 2010

Collegium Pharmaceutical receives Notice of Allowance from USPTO for DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has received Notice of Allowance from the U.S. Patent and Trademark Office for its patent application "Abuse-Deterrent Drug Formulations", US Patent Application Number 11/149,867. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.

20 May 2010

BioLife Solutions first-quarter revenue up 36% to $513,000

BioLife Solutions, Inc., announced today that Chairman and Chief Executive Officer Mike Rice issued the following letter to shareholders providing a general corporate update.

20 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

Patterson's consolidated sales for fourth-quarter fiscal 2010 up 4%

Patterson Companies, Inc. today reported consolidated sales of $812,762,000 for the fourth quarter of fiscal 2010 ended April 24, an increase of 4% from $779,884,000 in the year-earlier quarter. Internal growth accounted for 1% of the fourth quarter sales increase, with acquisitions and foreign currency adjustments accounting for the balance.

20 May 2010

New study uses NMR in drug design

A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.

20 May 2010

A.P. Pharma receives Nasdaq non-compliance notice

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).

20 May 2010

Healthiest Companies in America for 2010

Amid the glaring spotlight focused on healthcare reform in the U.S., Interactive Health Solutions today announced a list of the "Healthiest Companies in America" for 2010, a group of thirty-four corporations who have significantly reduced healthcare costs through employee participation in a prevention-based health program in the workplace.

20 May 2010

Treatment costs higher for CVD patients readmitted after leaving hospitals against medical advice

A University of Maryland School of Pharmacy study shows that among patients with cardiovascular disease (CVD) who discharged themselves from the hospital early the treatment cost if they are readmitted runs 9 percent higher compared to CVD patients who had been formally discharged.

20 May 2010

US subsidiary of Novartis disputes claims of discrimination

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG, strongly disputes the claims of past discrimination in the sales force during the period of 2002 to 2007.

20 May 2010

Update on Phase I clinical trials of Oncopore for treatment of cancer

The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the recent BIO conference in Chicago on Phase I clinical trials of Oncopore (LTX-315) for the treatment of cancer.

20 May 2010

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis, during an oral presentation at the American Thoracic Society 2010 International Conference May 14 - 19, 2010 in New Orleans, LA.

20 May 2010